Company Profile
Larimar Therapeutics Stock Price, News & Catalysts
- Ticker:
- LRMR
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
4.37 USD (+1.39%)
Close
Last updated: August 12, 2026
343M USD
Market cap
Why the stock is moving
As of Aug 12, 2026, LRMR closed up 1.39% at $4.37. No new same-company headline was identified in the current news window.
Company overview
Intracellular Protein Delivery
Larimar Therapeutics develops fusion proteins that deliver functional biological material into cells. Its lead program addresses a rare disease caused by deficiency of the intracellular protein frataxin.
Nomlabofusp
Nomlabofusp is a recombinant fusion protein designed to deliver human frataxin into the mitochondria of patients with Friedreich’s ataxia. The therapy is intended to address the underlying protein deficiency rather than only manage disease symptoms.
Accelerated-Approval Strategy
Larimar is working with the FDA on a BLA using skin frataxin as a biomarker and matched natural-history comparisons for clinical outcomes. A global confirmatory Phase 3 trial is planned to be underway at submission and uses change in the Upright Stability Score as its primary endpoint.
Platform Expansion
Beyond Friedreich’s ataxia, Larimar intends to use its intracellular delivery technology to create fusion proteins for other rare diseases caused by deficiencies in intracellular bioactive compounds.
Future catalysts
- Topline open-label nomlabofusp data expected in the second quarter of 2026.
- Start of screening for the confirmatory Phase 3 study expected in the second quarter of 2026, with first dosing around mid-2026.
- Nomlabofusp BLA submission seeking accelerated approval planned for June 2026.
- Potential U.S. launch targeted for the first half of 2027, subject to approval.
Recent news
- 01
- 02
- 03
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Larimar Therapeutics (LRMR)?
Larimar Therapeutics (LRMR) most recently closed at 4.37 USD, a +1.39% move versus the previous session.
What is the market cap of Larimar Therapeutics (LRMR)?
Larimar Therapeutics currently has a market capitalization of 343M USD on BioPharmSignal.
What does Larimar Therapeutics do?
Intracellular Protein Delivery Larimar Therapeutics develops fusion proteins that deliver functional biological material into cells. Its lead program addresses a rare disease caused by deficiency of the intracellular protein frataxin. Nomlabofusp Nomlabofusp is a recombinant fusion protein designed to deliver human frataxin into the mitochondria of patients...
On which exchange is LRMR stock listed?
Larimar Therapeutics (LRMR) is associated with NASDAQ, United States, Biopharma.
What is Intracellular?
Intracellular Protein Delivery Larimar Therapeutics develops fusion proteins that deliver functional biological material into cells.
Which conditions is Larimar Therapeutics targeting with Intracellular?
Larimar Therapeutics is associated with rare disease based on its company overview and current catalyst commentary.
How does Larimar Therapeutics describe recent progress with Intracellular?
Topline open-label nomlabofusp data expected in the second quarter of 2026. Start of screening for the confirmatory Phase 3 study expected in the second quarter of 2026, with first dosing around mid-2026. Nomlabofusp BLA submission seeking accelerated approval planned for June 2026. Potential U.S. launch targeted for the first half of 2027, subject to...
What is Protein?
Intracellular Protein Delivery Larimar Therapeutics develops fusion proteins that deliver functional biological material into cells.